Extrawell Pharmaceutical Holdings (HKSE:00858) Additional Paid-In Capital : HK$196.58 Mil(As of Mar. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Extrawell Pharmaceutical Holdings Additional Paid-In Capital?

Extrawell Pharmaceutical Holdings's quarterly additional paid-in capital stayed the same from Mar. 2023 (HK$196.58 Mil) to Sep. 2023 (HK$196.58 Mil) and stayed the same from Sep. 2023 (HK$196.58 Mil) to Mar. 2024 (HK$196.58 Mil).

Extrawell Pharmaceutical Holdings's annual additional paid-in capital stayed the same from Mar. 2022 (HK$196.58 Mil) to Mar. 2023 (HK$196.58 Mil) and stayed the same from Mar. 2023 (HK$196.58 Mil) to Mar. 2024 (HK$196.58 Mil).

Extrawell Pharmaceutical Holdings Additional Paid-In Capital Historical Data

The historical data trend for Extrawell Pharmaceutical Holdings's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Extrawell Pharmaceutical Holdings Additional Paid-In Capital Chart

Extrawell Pharmaceutical Holdings Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Additional Paid-In Capital

Get a 7-Day Free Trial

196.58

Extrawell Pharmaceutical Holdings Semi-Annual Data
	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															196.58	-	196.58	196.58	196.58

Extrawell Pharmaceutical Holdings Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Extrawell Pharmaceutical Holdings Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Extrawell Pharmaceutical Holdings's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Extrawell Pharmaceutical Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Extrawell Pharmaceutical Holdings Ltd (HKSE:00858) » Definitions » Additional Paid-In Capital

Traded in Other Exchanges

N/A

Address

979 King’s Road, Suites 2206-08, 22nd Floor, Devon House, Taikoo Place, Quarry Bay, Hong Kong, HKG

Website

http://www.extrawell.com.hk

Extrawell Pharmaceutical Holdings Ltd is an investment holding company. The company's operating segment includes Manufacturing; Trading and Gene Development. It generates maximum revenue from the Manufacturing segment. The manufacturing segment is engaged in the development, manufacture, and sales of pharmaceutical products. Its trading segment is engaged in the marketing and distribution of imported pharmaceutical products. The gene development segment is engaged in the commercial exploitation and development of genome-related technology. Geographically, it derives a majority of its revenue from China.

Executives

Mao Yumin	2201 Interest of corporation controlled by you
Biowindow Gene Development (hong Kong) Limited	2201 Interest of corporation controlled by you
Ease Gold Investments Limited	2201 Interest of corporation controlled by you
Jnj Investments Ltd	2201 Interest of corporation controlled by you
United Gene Group Ltd	2201 Interest of corporation controlled by you
United Gene Holdings Limited	2201 Interest of corporation controlled by you
United Gene International Holdings Group Limited	2101 Beneficial owner
Xie Yi	2201 Interest of corporation controlled by you
Huang Zhenping	2101 Beneficial owner
United Gene Industry Group Limited	2101 Beneficial owner
Chen Xuhua	2202 Interest of your spouse
Cheng Yong	2201 Interest of corporation controlled by you

Extrawell Pharmaceutical Holdings Headlines

No Headlines